Integra LifeSciences (IART)
(Delayed Data from NSDQ)
$12.31 USD
-0.83 (-6.32%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $12.30 -0.01 (-0.08%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth F Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
IART 12.31 -0.83(-6.32%)
Will IART be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IART based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IART
Compared to Estimates, Integra (IART) Q2 Earnings: A Look at Key Metrics
Integra LifeSciences (IART) Beats Q2 Earnings and Revenue Estimates
IART: What are Zacks experts saying now?
Zacks Private Portfolio Services
IART Stock May Rise on First Enrollment in AERA Pediatric Registry
Veracyte (VCYT) Down 13.6% Since Last Earnings Report: Can It Rebound?
Integra (IART) Up 2.3% Since Last Earnings Report: Can It Continue?
Other News for IART
Integra LifeSciences Holdings Corporation (IART) Q2 2025 Earnings Call Transcript
Q2 2025 Integra Lifesciences Holdings Corp Earnings Call Transcript
Integra LifeSciences Reports Q2 2025 Financial Results
Integra LifeSciences (IART) Adjusts FY25 Revenue Guidance
Integra Lifesciences Holdings Corp Reports Q2 Revenue of $415. ...